Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study

Background CD37 is expressed on B-cell lymphoid malignancies, thus making it an attractive candidate for targeted therapy in non-Hodgkin lymphoma (NHL). IMGN529 is an antibody-drug conjugate comprising a CD37-binding antibody linked to the maytansinoid DM1, a potent anti-mitotic agent. Methods This...

Descripción completa

Detalles Bibliográficos
Autores principales: Stathis, Anastasios, Flinn, Ian W., Madan, Sumit, Maddocks, Kami, Freedman, Arnold, Weitman, Steven, Zucca, Emanuele, Munteanu, Mihaela C., Lia Palomba, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153548/
https://www.ncbi.nlm.nih.gov/pubmed/29453628
http://dx.doi.org/10.1007/s10637-018-0570-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153548/
https://www.ncbi.nlm.nih.gov/pubmed/29453628
http://dx.doi.org/10.1007/s10637-018-0570-4

Ejemplares similares